TYO:4502 Revenue

In the fiscal year ending March 31, 2026, Takeda Pharmaceutical Company had annual revenue of 4.51T JPY, down -1.66%. Takeda Pharmaceutical Company had revenue of 1.09T in the quarter ending March 31, 2026, with 3.90% growth.

Revenue

4.51T

Revenue Growth

-1.66%

P/S Ratio

1.79

Revenue / Employee

94.95M

Employees

47,455

Market Cap

8.09T

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2026	4.51T	-75.83B	-1.66%
Mar 31, 2025	4.58T	317.79B	7.45%
Mar 31, 2024	4.26T	236.28B	5.87%
Mar 31, 2023	4.03T	458.47B	12.85%
Mar 31, 2022	3.57T	371.20B	11.61%
Mar 31, 2021	3.20T	-93.38B	-2.84%
Mar 31, 2020	3.29T	1.19T	56.93%
Mar 31, 2019	2.10T	-	-

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Toho Holdings	1.55T
Eisai	825.38B
Shionogi &	499.68B
Sumitomo Pharma	453.29B
Towa Pharmaceutical	273.71B
Sawai Group Holdings	201.68B
Tsumura & Co.	192.62B
Nippon Shinyaku	170.77B

Revenue Rankings

Takeda Pharmaceutical Company News

8 days ago - Takeda Pharmaceutical is Now Oversold (TAK) - Nasdaq
11 days ago - Takeda Ordered To Pay $884.9 Mln In AMITIZA Antitrust Case; To Revise FY25 Results - Nasdaq
12 days ago - Takeda Pharmaceutical (TAK) Found Guilty in Generic Drug Delay Conspiracy - GuruFocus
12 days ago - Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda - Business Wire
12 days ago - Jury finds Takeda caused about $885M in damages over generic delay, Reuters says - TheFly
12 days ago - Takeda engaged in antitrust scheme to delay generic constipation drug, US jury finds - Reuters
12 days ago - Takeda told to pay hundreds of millions for generic drug delay, Bloomberg says - TheFly
12 days ago - Takeda ordered by pay hundreds of millions in antitrust case, Bloomberg says - TheFly

More News